Researcher Spotlight: Raphael Eric Steiner, MD University of Texas MD Anderson Cancer Center Primary mediastinal large B-cell lymphoma (PMLBCL), a type of diffuselarge B-cell lymphoma (DLBCL), affects predominantly adolescents and young adults and is usually treated with chemo-immune therapy with…
Researcher Spotlight: Christina Lee, MD Memorial Sloan Kettering Cancer Center It has become increasingly apparent that normal immune cells are important in disease progression and therapy resistance in lymphoma. Studies from a clinical trial of two targeted therapies, ibrutinib (Imbruvica)…
Researcher Spotlight: Boyu Hu, MD University of Utah/Huntsman Cancer Institute Gene mutations and chromosomal alterations found in relapsed/refractorychronic lymphocytic leukemia (CLL) makes the disease more resistant to currently approved therapies and prone to earlier relapses. While these gene changes are…
Researcher Spotlight: Jamie Flerlage, MD St. Jude Children’s Research Hospital, Inc. Nodular lymphocyte-predominant Hodgkin lymphoma(NLPHL) is a rare type of Hodgkin lymphoma (HL) thattends to grow more slowly than HL and requires differenttreatment. Despite its high cure rates, NLPHL is…
Researcher Spotlight: Pamela Allen, MD Emory University/Winship Cancer Institute Patients with advanced-stage cutaneous T-cell lymphoma (CTCL) have a median survival of fewer than five years and often experience debilitating itchy red skin. Patients with CTCL may be treated with extracorporeal…
Researcher Spotlight: Paolo Strati, MD The University of Texas Macrophages are large white blood cells that present antigens within the human immune system, an important step in signaling the immune system to attack disease,. Researchers are developing therapies which help increase the activity…
Researcher Spotlight: Yazeed Sawalha, MD Cleveland Clinic Patients with indolent non-Hodgkin lymphoma who relapse or have refractory lymphoma that does not respond to treatment still have poorer outcomes, with many of the current available treatments having either limited benefit or significant side effects.…
Researcher Spotlight: Allison Rosenthal, DO Mayo Clinic Arizona Mantle cell lymphoma (MCL) can present in a variety of ways, from slow-growing indolent to more aggressive forms with poorer outcomes. Currently a patient’s treatment plan is largely based on patient age…
Researcher Spotlight: Reid Merryman, MD Dana-Farber Cancer Institute Marginal zone lymphoma (MZL) is a slow-growing B-cell NHL that has a relatively low number of new diagnoses each year. As a result, few clinical trials are available for MZL patients, including…
Researcher Spotlight: Rahul Lakhotia, MBBS National Institutes of Health Indolent lymphomas frequently require multiple lines of treatment as the disease recurs; the frequency of treatment makes it important to balance efficacy with potential toxicities (side effects). Dr. Lakhotia’s LCRMP project tests a new…
